Ifosfamide, carboplatin, and etoposide for neuroblastoma
Open Access
Abstract
BACKGROUND: The authors report a retrospective analysis of high‐dose ifosfamide, carboplatin, and etoposide (HD‐ICE) for patients with refractory or relapsed neuroblastoma (NB). A major reason for using this regimen was the long time since patients received previous treatment with a platinum compound. The authors also summarized the published experience on ICE in patients with NB.METHODS: Treatment comprised ifosfamide (2000 mg/m2 daily for 5 days), carboplatin (500 mg/m2 daily for 2 days), and etoposide (100 mg/m2 daily for 5 days). Patients who had poor hematologic reserve (platelet count 36% in phase 1 and 2 studies (in which less comprehensive staging evaluations were used) that involved resistant NB and >70% in induction for newly diagnosed NB.CONCLUSIONS: HD‐ICE is appealing as salvage treatment or consolidative therapy because of its anti‐NB activity and the low risk of major nonhematologic toxicity. PBSC support is unnecessary for patients who had intact hematologic reserve. Cancer 2013. © 2012 American Cancer Society.Keywords
This publication has 40 references indexed in Scilit:
- Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group StudyJournal of Clinical Oncology, 2011
- Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastomaEuropean Journal of Cancer, 2011
- High-dose cyclophosphamide–irinotecan–vincristine for primary refractory neuroblastomaEuropean Journal of Cancer, 2011
- Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: A report from the Childrens Oncology GroupPediatric Blood & Cancer, 2010
- Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium StudyJournal of Clinical Oncology, 2009
- Iodine-131—Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I StudyJournal of Clinical Oncology, 2009
- Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trialJournal of Cancer Research and Clinical Oncology, 2007
- Topotecan and Etoposide in the Treatment of Relapsed High-risk NeuroblastomaJournal of Pediatric Hematology/Oncology, 2007
- Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experiencePediatric Blood & Cancer, 2004
- Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: A single hospital experienceMedical and Pediatric Oncology, 1996